Please ensure Javascript is enabled for purposes of website accessibility

Will This News Stop Ocugen Shares in Their Tracks?

By Adria Cimino – Jun 14, 2021 at 5:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This high flyer is still up more than 260% this year.

Ocugen (OCGN 4.00%) soared to stock market stardom earlier this year after becoming a coronavirus vaccine stock almost overnight. The company signed a deal with Bharat Biotech to co-commercialize Bharat's near-to-market coronavirus vaccine candidate in the U.S. In recent days, the companies expanded the deal to include Canada as well.

From the start of the year to a peak in February, Ocugen shares rose more than 760%. But in recent weeks, they lost their luster -- at least for some investors. The stock is down about 50% from that peak. And just last week, Ocugen announced news that could remove even more of the luster. Let's take a look what the company said and whether it will put a halt on this once unstoppable stock.

An investor sitting in front of her laptop reads something on her phone.

Image source: Getty Images.

Following the FDA's advice

Ocugen said that it won't pursue Emergency Use Authorization (EUA) in the U.S. for its vaccine candidate -- known as Covaxin. That's upon recommendation from the U.S. Food and Drug Administration. The FDA recently reviewed the Covaxin master file and advised Ocugen to opt for a standard submission for approval.

That means a much slower time to market. EUA reviews during the pandemic have taken a few weeks. The review process for Biologics License Applications (BLA) usually takes six to 10 months. But we can add even more time to that. That's because the FDA also requested more data from Ocugen. Bharat is currently conducting a phase 3 trial in India. The companies already had submitted interim results from that trial to the FDA. Now, Ocugen says it expects a new clinical trial may be needed to support its regulatory request.

A late-stage trial to support an EUA took market leaders Pfizer and Moderna each about four months. But a clinical trial to support a BLA likely will take longer. Standard approval will require months of additional follow up data. For example, Pfizer and Moderna won EUAs in December. And they are just now requesting full regulatory approval. 

How bad is this news?

So, how bad is this news for Ocugen and investors? Well, even if the FDA granted Ocugen an EUA, I haven't been optimistic about the company's chances of selling Covaxin in the U.S. right away. The U.S. already bought enough doses to vaccinate the entire population. It seemed unlikely the U.S. would order Covaxin in the near term.

That said, an EUA would have resulted in two positive elements: Ocugen could have gotten the commercial engine going -- and it would have avoided the cost of conducting a new clinical trial.

Now, negotiating contracts and planning a clinical trial represent hurdles. It may be difficult for Ocugen to seal a future Covaxin supply deal with the U.S. at this point. It seems more likely the U.S. would opt for the three vaccines currently authorized. And organizing and funding a clinical trial represents a significant investment.

Luckily for Ocugen, it may have the opportunity to sell Covaxin in Canada in the near term. The company is proceeding with its plan to file for expedited authorization there. Canada ordered enough vaccine doses. But supply has been short. So, the country may be willing to authorize the vaccine candidate -- and place an order. Still, I'm not sure this would represent a major source of revenue. It's important to keep in mind the terms of the co-commercialization deal: Ocugen gets to keep 45% of vaccine profit. Bharat takes the rest.

The long-term picture

So far, we've looked at the near-term picture. But Ocugen still may win FDA approval farther down the road. Experts say the coronavirus will be with us for a long time. And that means we'll continue to need vaccines. Of course, Ocugen could land a U.S. vaccine supply deal in the future. But I'm not overly confident about the company's ability to take enough market share to make its Bharat partnership worthwhile.

Today's vaccine leaders are working on boosters and vaccine updates. And other latecomers are working on game-changing technologies such as oral vaccines or nasal spray formulations. It will be difficult for Ocugen to stand out among these players.

So, let's get back to the stock price. Here's what performance looks like so far this year. The latest drop -- 28% in one day -- happened when Ocugen announced its new U.S. regulatory plan.

OCGN Chart

OCGN data by YCharts

Was that drop temporary? Or will the news stop Ocugen in its tracks? I think it will slow things down quite a bit. Many investors were counting on Ocugen entering the U.S. market soon since Covaxin's development in India is nearly complete. A significant delay and the possibility of a new trial add a lot of risk to this stock. And the potential for reward isn't looking all that certain. Of course, any positive news from Canadian regulators could offer Ocugen a lift. But I'm not optimistic about sustained gains right now.

It will be interesting to watch how the Ocugen story unfolds. And the best place to do that is on the sidelines.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Ocugen, Inc. Stock Quote
Ocugen, Inc.
OCGN
$1.82 (4.00%) $0.07
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.09 (0.59%) $0.26
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$122.23 (2.12%) $2.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
327%
 
S&P 500 Returns
105%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.